WELLESLEY HILLS, Mass., May 10, 2011 /PRNewswire/ — On Friday,
June 10, 2011 at twelve o’clock noon, NMT Medical, Inc.
intellectual property, which has been assigned to Joseph F. Finn,
Jr., C.P.A. (“Finn”) of the firm Finn, Warnke & Gayton, LLP
will be liquidated for the benefit of NMT Medical creditors.
NMT Medical, Inc. was an advanced medical technology company
that designed, developed, manufactured and marketed proprietary
implant technologies that allowed interventional cardiologists to
treat structural heart disease through minimally invasive,
catheter-based procedures. More than 32,000 patients have
been treated globally with its minimally invasive, catheter-based
implant technology.
The intellectual property, patents, etc. will be sold at a
sealed bid sale on Friday, June 10, 2011 at noon. Persons
interested in bidding must sign a Confidentiality Disclosure
Agreement (“CDA”) obtained from Finn’s Office –
jffinnjr@finnwarnkegayton.com or 781-237-8840. They will
then receive a bid package.
About Joseph F. Finn, Jr., C.P.A.
Joseph F. Finn, Jr., C.P.A. is a founding partner of the firm
Finn, Warnke & Gayton (www.finnwarnkegayton.com),
Certified Public Accountants of Wellesley Hills, Massachusetts.
He works primarily in the area of management consulting for
distressed enterprises, bankruptcy accounting and related matters,
such as assignee for the benefit of creditors and liquidating agent
for a corporation. He has been involved in a number of loan
workouts and bankruptcy cases for thirty-seven (37) years.
His most recent Assignments for the Benefit of Creditors in
the biotech field include Spherics, Inc., ActivBiotics, Inc.,
Prospect Therapeutics, Inc., EPIX Pharmaceuticals, Inc. and Source
MDx.
For further information, please contact Joseph F. Finn, Jr.,
C.P.A. at 781-237-8840
‘/>”/>
